QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text (PDF) All Versions of this Article: jpet.106.114223v1 320/2/926    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ko, M.-C. Articles by Woods, J. H. Search for Related Content PubMed PubMed Citation Articles by Ko, M.-C. Articles by Woods, J. H.

BEHAVIORAL PHARMACOLOGY

Cocaine Esterase: Interactions with Cocaine and Immune Responses in Mice

Departments of Pharmacology (M.C.K., L.D.B., D.N., R.K.S., Z.D.C., J.H.W.) and Pathology (A.A.B., N.W.L.), University of Michigan, Medical School, Ann Arbor, Michigan

Received September 18, 2006; accepted November 16, 2006.

	Abstract

Top Abstract Materials and Methods Results Discussion References

 
Cocaine esterase (CocE) is the most efficient protein catalyst for the hydrolysis of cocaine characterized to date. The aim of this study was to investigate the in vivo potency of CocE in blocking cocaine-induced toxicity in the mouse and to assess CocE's potential immunogenicity. Cocaine toxicity was quantified by measuring the occurrence of convulsions and lethality. Intravenous administration of CocE (0.1–1 mg) 1 min before cocaine administration produced dose-dependent rightward shifts of the dose-response curve for cocaine toxicity. More important, i.v. CocE (0.1–1 mg), given 1 min after the occurrence of cocaine-induced convulsions, shortened the recovery time after the convulsions and saved the mice from subsequent death. Effects of repeated exposures to CocE were evaluated by measuring anti-CocE antibody titers and the protective effects of i.v. CocE (0.32 mg) against toxicity elicited by i.p. cocaine (320 mg/kg) (i.e., 0–17% occurrence of convulsions and lethality). CocE retained its potency against cocaine toxicity in mice after a single prior CocE exposure (0.1–1 mg), and these mice did not show an immune response. CocE retained similar effectiveness in mice after three prior CocE exposures (0.1–1 mg/week for 3 weeks), although these mice displayed 10-fold higher antibody titers. CocE partially lost effectiveness (i.e., 33–50% occurrence of convulsions and lethality) in mice with four prior exposures to CocE (0.1–1 mg/2 week for four times), and these mice displayed 100-fold higher antibody titers. These results suggest that CocE produces robust protection and reversal of cocaine toxicity, indicating CocE's therapeutic potential for acute cocaine toxicity. Repeated CocE exposures may increase its immunogenicity and partially reduce its protective ability.

The sequelae of a cocaine overdose include generalized clonic-tonic seizures and status epilepticus capable of producing long-term neurological impairment and death (Kramer et al., 1990; Benowitz, 1993). Cocaine-induced seizures can be resistant to anticonvulsants such as benzodiazepines and are considered to be a major determinant of cocaine-related lethality (Dhuna et al., 1991; Benowitz, 1993). Unfortunately, there is no effective treatment for cocaine abuse and toxicity, and the search for effective and safe treatments continues (Dickerson and Janda, 2005; Sofuoglu and Kosten, 2005; Vocci et al., 2005).

Cocaine blocks the reuptake of dopamine, norepinephrine, and serotonin after binding to monoamine transporters (Hoffman et al., 1991; Kilty et al., 1991; Pacholczyk et al., 1991; Ramamoorthy and Blakely, 1999). In addition, cocaine produces local anesthetic effects through its blockade of sodium channels (Nettleton and Wang, 1990; Wright et al., 1997; O'Leary and Chahine, 2002). Cocaine's primary action for causing cardiac arrhythmias and sudden death may be its blockade of sodium and potassium channels (Crumb and Clarkson, 1990; Zhang et al., 2001; Bauman and DiDomenico, 2002; Wilson and Shelat, 2003). The inherent difficulties in selectively targeting different receptor/ion channel sites that correspond to the multiple sites of actions of cocaine have led to the development of protein-based therapeutics. One approach to reducing the effects of cocaine is to eliminate it quickly by administration of esterases that rapidly metabolize cocaine. Butyrylcholinesterase (BChE), the major cocaine-metabolizing enzyme present in the plasma of humans and other mammals (Lynch et al., 1997; Mattes et al., 1997), and a bacterial cocaine esterase (CocE) (Bresler et al., 2000; Cooper et al., 2006) have been explored as potential enzymatic therapeutics.

CocE was originally identified in the bacterium Rhodococcus sp. strain MB1, which grows in the rhizosphere soil of the cocaine-producing plant Erythroxylum coca (Bresler et al., 2000). The bacterium uses cocaine as its sole source of carbon and nitrogen by synthesizing CocE to initiate metabolism of cocaine. CocE is a globular, 574-amino acid enzyme with a molecular mass of 65 kDa and is the most efficient protein catalyst for the hydrolysis of cocaine characterized to date (Bresler et al., 2000; Larsen et al., 2002; Turner et al., 2002; Rogers et al., 2005). The hydrolytic rate constant of this enzyme (k_cat/K_m) is 1000-fold higher than that of BChE and 10⁵- and 10⁶-fold faster than catalytic antibodies such as monoclonal antibody 15A10 (Deng et al., 2002; Turner et al., 2002). A recent in vivo study in rats has further demonstrated CocE's superior catalytic efficiency and selectivity for cocaine compared with BChE (Cooper et al., 2006). In particular, i.v. CocE (1 mg with 1-min pretreatment) protected 100% of rats receiving i.p. cocaine (180 mg/kg), but i.v. BChE (13 mg) (i.e., a 10-fold multiple of the molar equivalent dose of CocE) failed to protect rats from cocaine-induced lethality (Cooper et al., 2006).

Although the catalytic efficiency of CocE makes it an ideal candidate for an improved therapy for cocaine acute toxicity, it has been speculated that this bacterial enzyme would be rapidly cleared via proteolysis and immune surveillance (Rogers et al., 2005). CocE was found to have a remarkably short half-life (i.e., 10 min) in rat plasma and accordingly to have a short duration of protective effects (Cooper et al., 2006). Given CocE's rapid clearance and poor thermostability, it is possible that CocE may have reduced immunogenicity. It is important to investigate to what degree CocE exposure is liable to produce an immune response and how CocE's immunogenicity affects its ability to protect against cocaine toxicity. The aim of this study was therefore to investigate whether CocE could prevent and reverse cocaine-induced toxicity in mice and whether repeated exposures of CocE could increase immunological responses and change the effectiveness of CocE in vivo.

	Materials and Methods

Top Abstract Materials and Methods Results Discussion References

 
Subjects
Male NIH-Swiss mice (25–32 g) were obtained from Harlan (Indianapolis, IN) and were housed in groups of six mice per cage. All mice were allowed ad libitum access to food and water and were maintained on a 12-h light/dark cycle with lights on at 6:30 AM in a room kept at a temperature of 21 to 22°C. Experiments were performed in accordance with the Guide for the Care and Use of Laboratory Animals as adopted and promulgated by the National Institutes of Health (NIH publication 85-23, revised 1996). The experimental protocols were approved by the University Committee on the Use and Care of Animals at the University of Michigan.

Procedures
Behavioral Assays. Cocaine-induced toxicity was characterized by the occurrence of convulsions and lethality. Cocaine-induced convulsions were defined as loss of righting posture for at least 5 s with the simultaneous presence of clonic limb movements (Gasior et al., 2000; Daniels et al., 2006). Lethality was defined as cessation of observed movement and respiration. After i.p. cocaine administration, mice were immediately placed individually in Plexiglas containers (16 x 28 x 20 cm high) for observation. The presence or absence of convulsions and lethality and the time to affected responses were recorded for 60 min after cocaine administration.

Intravenous Administration. The mouse was placed in a small restraint chamber (outer tube diameter: 30 mm, inner tube diameter: 24 mm, model no. BS4-34-0012; Harvard Apparatus Inc., Holliston, MA) that left the tail exposed. The tail was cleansed with an alcohol wipe and a 30G1/2 precision glide needle (Fisher Scientific Co., Pittsburgh, PA) was inserted into one of the side veins for infusion. The i.v. injection volume of CocE was 0.2 ml/mouse. To staunch the bleeding, sterile gauze and pressure were applied to the injection site.

Serum Collection. Mice have large veins draining the eye and submandibular area that meet at the rear of the cheek pouch. This vein provides a convenient and consistent source of blood (i.e., cheek-pouch blood sampling). A mouse bleeding lancet (GoldenRod 4.0 mm animal lancet; MEDIpoint Inc., Mineola, NY) was used to puncture this submandibular vein. The blood was collected in a tube from the puncture and was prepared as serum samples (50 ml/mouse) for CocE antibody titer determinations. As soon as the blood was collected, sterile gauze and pressure were applied at the puncture site to minimize the bleeding, and the mouse was returned to its home cage.

Immunological Determination. A direct enzyme-linked immunosorbent assay specific for anti-CocE antibodies was set up using a standard protocol. CocE was used (1 µg/ml) to coat a 96-well microtiter plate using borate-buffered saline (1.5 M NaCl, 0.5 M H₃BO₃, and 1.0 M NaOH) to resuspend CocE (50 µl/well). The coating plates were left overnight at 4°C. The coating buffer was removed the following morning, and the plates were blocked with 2% normal goat serum in phosphate-buffered saline (PBS) for 1 h at 37°C and washed three times. Serum from the various groups of mice was serially diluted in 50 µl of PBS in the wells in a range of 10² to 10⁷, and samples were run in duplicate. The plates were covered and incubated for 1 h at 37°C. Subsequently, the plates were washed three times, and 50 µl/well goat anti-mouse IgG peroxidase-labeled antibody diluted 1:400 was added. The plates were then washed three times, and 100 ml of peroxidase substrate solution (OPD dissolved in citrate/phosphate buffer) was added to each well. After a 5- to 10-min incubation (based upon color development in the positive controls), the reaction was stopped using 3 MH₂SO₄ (50 µl/well). The plates were read at 490 nm, and titer was determined by the highest dilution that showed increases over background absorbance. Positive controls were derived by immunizing BALB/c mice with 100 µgin 100 µl of CocE emulsified in incomplete Freund's adjuvant (IFA) (Sigma-Aldrich, St. Louis, MO) by i.p. administration.

Experimental Designs
The first part of the study was to determine the ability of CocE to protect and reverse cocaine-induced toxicity. In the protection study, CocE (0.1, 0.32, and 1 mg) was administered i.v. 1 min before administration of several doses of i.p. cocaine (180, 320, 560, 1000, and 1800 mg/kg). Dose-response curves of cocaine-induced convulsions and lethality in the absence or presence of different doses of CocE were determined to demonstrate the in vivo protective effects of CocE. After a dose response of CocE was established, the dosing condition of i.p. cocaine (320 mg/kg) in the presence of i.v. CocE (0.32 mg) was chosen to study the time course of CocE's protective effects. Prevention of cocaine toxicity by CocE was determined by using different CocE pretreatment time points (i.e., 1, 5, 10, and 20 min before cocaine administration). In the rescue study, CocE (0.1, 0.32, and 1 mg) was administered i.v. within the 1st min after the occurrence of convulsions induced by i.p. cocaine (100 mg/kg). This cocaine dose was chosen because it produced convulsions in 100% of mice and lethality in 40 to 60% of mice based on our pilot study. The interval between the onset of convulsion and lethality was 4 to 5 min, which allowed an opportunity for CocE administration to rescue the mouse from cocaine (i.e., 100 mg/kg) intoxication.

The second part of the study was to determine how prior exposure to CocE evoked immunological responses and how immunogenicity affected CocE's protection against cocaine toxicity. Three CocE dosing regimens were used to investigate whether CocE retained its effectiveness after repeated administration and whether anti-CocE antibody titers increased accordingly. The experimental condition of i.p. cocaine (320 mg/kg) in the presence of i.v. CocE (0.32 mg, 1-min pretreatment) was chosen to determine CocE's ability to prevent cocaine toxicity. Anti-CocE antibodies were determined from serum samples collected 24 h before each toxicity test. The first dosing regimen gave mice a single i.v. exposure to CocE (0, 0.1, 0.32, or 1 mg), and CocE's effectiveness was assessed in these pretreated mice 1 month later. The second dosing regimen gave mice three i.v. exposures to CocE [0–1 mg/week for 3 weeks (once per week for 3 weeks)] and determined CocE's effectiveness 1 week later. One additional group was used to immunize mice by using 0.1 mg of CocE in conjunction with CFA and IFA [week 1: i.p. CocE (0.1 mg) + s.c. CocE (0.1 mg) + i.p. CFA (0.1 mg) + s.c. CFA; week 2: i.p. CocE (0.1 mg) + i.p. IFA (0.1 mg); week 3: i.p. CocE (0.1 mg) + i.p. IFA (0.1 mg); week 4: serum collection and behavioral toxicity test] to investigate whether a large increase in the titer number significantly reduced CocE's effectiveness in immunized mice. The third dosing regimen gave mice four i.v. exposures of CocE [0–1 mg/2 weeks for four times and determined CocE's effectiveness in these pretreated mice 2 weeks later.

View larger version (26K): [in this window] [in a new window]   Fig. 1. Protective effects of CocE against cocaine-induced toxicity. CocE (milligrams) was administered i.v. 1 min before cocaine administration (milligrams per kilogram i.p.). Left, dose-response curves of cocaine-induced convulsions and lethality in the absence or presence of CocE. Each data point represents the percentage of mice (n = 6 for each dosing condition) exhibiting cocaine-induced convulsions or lethality. Right, time to toxic effects of cocaine in the absence or presence of CocE in the dosing condition that 100% mice showed affected responses. Each value represents the mean ± S.E.M. (n = 6). *, p < 0.05, significant difference from the condition of cocaine alone. See Materials and Methods for other details.

Drugs
Cocaine hydrochloride (Mallinckrodt, St. Louis, MO) was dissolved in sterile water and was administered i.p. at a volume of 0.01 ml/g. CocE (purified and supplied by Drs. D. Narasimhan and R. K. Sunahara; see details in Cooper et al., 2006) was diluted to different concentrations in PBS and administered intravenously at a volume of 0.2 ml/mouse.

	Results

Top Abstract Materials and Methods Results Discussion References

 
Intraperitoneal administration of cocaine dose-dependently produced convulsions (ED_100conv: 100 mg/kg) and lethality (LD₁₀₀: 130 mg/kg) in mice (Fig. 1, left). The intervals between cocaine administration and onset of convulsions or death were 2.4 ± 0.3 and 5.4 ± 0.5 min (mean ± S.E.M.), respectively, after cocaine (130 mg/kg), yielding a convulsion-death interval of 3 min (Fig. 1, right). The intervals between cocaine administration and onset of convulsions or death were 1.5 ± 0.2 and 3.0 ± 0.2 min, respectively, after cocaine (180 mg/kg), yielding a convulsion-death interval of approximately 1.5 min.

Pretreatment with CocE (i.e., 1 min before cocaine administration) dose-dependently protected mice against cocaine-induced convulsions and lethality (Fig. 1, left). In particular, CocE at 0.32 and 1 mg produced 10- and 18-fold shifts, respectively, in the dose-response curve for cocaine-induced convulsions, such that 1000 and 1800 mg/kg cocaine (i.e., doses of ED_100conv) were required to surmount the protective properties of CocE. Likewise, CocE at 0.32 and 1 mg produced 8- and 14-fold shifts in the dose-response curve for cocaine-induced lethality by increasing the LD₁₀₀ dose to 1000 and 1800 mg/kg, respectively. Although 0.32 and 1 mg of CocE did not protect mice receiving 1000 or 1800 mg/kg cocaine, the time to the measured responses after cocaine administration was increased significantly (p < 0.05) (Fig. 1, right).

Pretreatment with CocE produced a time-dependent protection against cocaine-induced convulsions and lethality (Fig. 2). When i.v. CocE (0.32 mg) was administered 1 and 5 min before administration of i.p. cocaine (320 mg/kg), 100 and 67% of mice were saved, respectively. CocE's protective effects were completely reduced when mice received CocE 20 min before cocaine administration.

View larger version (16K): [in this window] [in a new window]   Fig. 2. Time course of protective effects of CocE against cocaine toxicity. Each data point represents the percentage of mice (n = 6 for each dosing condition) exhibiting cocaine-induced convulsions or lethality. CocE (0.32 mg i.v.) was administered 1, 5, 10, or 20 min before cocaine administration (320 mg/kg i.p.). *, p < 0.05, significant difference from the 20-min CocE pretreatment group showing 100% affected. See legend to Fig. 1 for other details.

View larger version (17K): [in this window] [in a new window]   Fig. 3. Effects of CocE in reversing cocaine-induced toxicity. CocE (milligrams) was administered i.v. within the 1st min after the occurrence of convulsions induced by i.p. cocaine (100 mg/kg). A and B, the occurrence of convulsions and the interval between cocaine administration and onset of convulsions after mice received 100 mg/kg cocaine. C, time to recovery from convulsions after CocE administration. D and E, occurrence of lethality and the interval between cocaine administration and onset of death in mice with or without postinjection of CocE. Each data point represents the percentage of mice (n = 8 for each dosing condition) exhibiting cocaine-induced convulsions or lethality. Each value represents the mean ± S.E.M. **, p < 0.01; *, p < 0.05, significant difference from the group not receiving CocE (i.e., PBS-treated group). See Materials and Methods for other details.

Effects of repeated exposures to CocE were evaluated by measuring the protective effects of i.v. CocE (0.32 mg) against toxicity elicited by i.p. cocaine (320 mg/kg) and the antibody titers (Figs. 4, 5, 6). One prior CocE exposure (0.1–1 mg) did not change the ability of CocE to prevent cocaine toxicity as i.v. CocE (0.32 mg) with 1-min pretreatment saved 83 to 100% of mice receiving i.p. cocaine (320 mg/kg) (Fig. 4, top and middle). In addition, this dosing regimen did not increase anti-CocE antibody titers (Fig. 4, bottom). Three prior CocE exposures also did not reduce the effectiveness of CocE as CocE retained its ability to protect against cocaine toxicity. Intravenous CocE (0.32 mg) saved 100% of mice receiving i.p. cocaine (320 mg/kg) (Fig. 5, top and middle). Nevertheless, this dosing regimen produced a 10-fold increase in the anti-CocE antibody titers irrespective of the dose of CocE given (Fig. 5, bottom). In contrast, mice immunized with Freund's adjuvant showed a 1000-fold increase of antibody titers, and CocE lost its ability to prevent cocaine-induced convulsions and lethality (i.e., the rightmost bars in Fig. 5).

View larger version (17K): [in this window] [in a new window]   Fig. 4. Effects of a single prior CocE exposure on the effectiveness of CocE. The protective effects of i.v. CocE (0.32 mg, 1-min pretreatment) against i.p. cocaine (320 mg/kg) were tested in mice 1 month after they received a single i.v. administration of CocE. The anti-CocE antibody titers were determined from serum samples collected 24 h before the toxicity test. Each value represents the percentage of mice affected or the mean ± S.E.M. (n = 6).

View larger version (25K): [in this window] [in a new window]   Fig. 5. Effects of three prior CocE exposures on the effectiveness of CocE. The protective effects of i.v. CocE (0.32 mg, 1-min pretreatment) against i.p. cocaine (320 mg/kg) were tested in mice 1 week after they received three exposures to various doses of i.v. CocE (0–1 mg/week for 3 weeks). The rightmost bars (i.e., 0.1/FA) illustrate the effects of 0.1 mg of CocE in conjunction with CFA/IFA under the same dosing regimen. The antibody titers were determined from serum samples collected 24 h before the toxicity test. Each value represents the percentage of mice affected or the mean ± S.E.M. (n = 6). **, p < 0.01; *, p < 0.05, significant difference from the group not receiving prior CocE exposures. See Materials and Methods for other details.

View larger version (26K): [in this window] [in a new window]   Fig. 6. Effects of four prior CocE exposures on the effectiveness of CocE. The protective effects of i.v. CocE (0.32 mg, 1-min pretreatment) against i.p. cocaine (320 mg/kg) were tested in mice 2 weeks after they received repeated i.v. CocE (0–1 mg/2 weeks for four times). The antibody titers were determined from serum samples collected 24 h before the toxicity test. Each value represents the percentage of mice affected or the mean ± S.E.M. (n = 6). **, p < 0.01, significant difference from the group not receiving prior CocE exposures. See Materials and Methods for other details.

View larger version (23K): [in this window] [in a new window]   Fig. 7. Relationship between the antibody titer numbers and affected responses of mice receiving prior CocE exposures. Symbols represent subjects tested for the protective effects of CocE against cocaine-induced toxicity under different dosing regimens as shown in Figs. 4, 5, and 6. Open symbols, measured antibody titer number of each mouse that did not exhibit convulsions or lethality; filled symbols, measured antibody titer number of each mouse that exhibited convulsions and/or lethality. See legends to Figs. 4, 5, and 6 for other details.

	Discussion

Top Abstract Materials and Methods Results Discussion References

 
This study showed that i.v. pretreatment with CocE dose-dependently protected mice from cocaine-induced convulsions and lethality. A dramatic shift (i.e., 10- to 20-fold) to the right in the dose-response curve of cocaine in producing convulsions and lethality was afforded by both 0.32 and 1 mg of CocE. These dose-dependent rightward shifts produced by CocE are profound. No other reported agents are able to shift the dose-response curve for cocaine toxicity to this extent (Gasior et al., 2000; Carrera et al., 2005; Daniels et al., 2006). These findings further support the first in vivo study of CocE in rats demonstrating CocE's rapid and robust protection against cocaine-induced lethality (Cooper et al., 2006). It will be valuable to investigate whether other effects of cocaine such as cardiovascular and local anesthetic effects can be antagonized by CocE. Interestingly, i.v. BChE (13 mg) (i.e., a 10-fold multiple of the molar equivalent dose to CocE) failed to protect rats from i.p. cocaine (180 mg/kg)-induced lethality (Cooper et al., 2006). In our pilot study, BChE (1 mg) also failed to protect against the lethality produced by 320 mg/kg cocaine in this mouse toxicity assay (M.-C. Ko, L. D. Bowen, and J. H. Woods, unpublished data). BChE only protected rats from cardiovascular changes and convulsions elicited by small to moderate doses of cocaine (1–80 mg/kg) (Lynch et al., 1997; Mattes et al., 1997). Several BChE mutants with improved catalytic efficiency have been engineered (Pan et al., 2005). It will be important to study and compare the protective effects of these BChE mutants with those of CocE in the rodent model of cocaine overdose.

The duration of CocE's protection against cocaine toxicity is short. CocE given 10 min before cocaine only protected 50% of mice from cocaine lethality (Fig. 2). Although the duration of CocE's esteratic activity in mouse plasma is unknown, CocE was found to have a short half-life (10 min) in rat plasma (Cooper et al., 2006). Preliminary in vitro data also suggested that CocE undergoes a temperature-dependent inactivation with a t_1/2 of 15 min at 37°C (P. Mierzejewski and R. K. Sunahara, personal communication). These findings may explain in part the fact that CocE not only decreased the potency of cocaine in producing convulsions and lethality but also prolonged the time to exhibit convulsions and lethality when 100% of mice with CocE pretreatment were affected (Fig. 1). Nevertheless, CocE's short duration of action should not detract from its potential in the treatment of acute cocaine overdose, although it probably prevents its usefulness in the treatment of cocaine abuse (i.e., self-administration). A compound that has any use in the treatment of drug abuse, particularly if it acts to eliminate the action of the abused drug, must have an extended duration of action. It is possible and important to design a CocE mutant with improved thermostability by using combinational chemistry and amino acid mutation.

A pivotal finding from this study is that CocE given after the occurrence of convulsions not only shortened the duration of convulsions but also saved mice from subsequent lethality (Fig. 3). Previous studies have shown that postcocaine administration of cocaine-metabolizing enzymes, such as BChE and CocE, can protect against cocaine toxicity (Lynch et al., 1997; Mattes et al., 1997; Cooper et al., 2006). What is novel in the present study is that CocE can reverse cocaine toxicity when it is given at a time point after the occurrence of convulsions (i.e., postcocaine versus postcocaine-convulsions). As mentioned previously under Materials and Methods, i.p. cocaine (100 mg/kg) provided only a 4- to 5-min window of opportunity for CocE's rescue. The temporal profile of the mouse's responses to cocaine overdose does not simulate the situation of an emergency department visit for which the interval between cocaine overdose and treatment will be longer. It would be valuable to assess CocE's ability to reverse the effects of cocaine in nonhuman primates before initiating clinical trials.

Although both in vitro and in vivo studies have demonstrated that CocE is the most efficient protein catalyst for hydrolyzing cocaine characterized to date (Larsen et al., 2002; Turner et al., 2002; Cooper et al., 2006), CocE is a large, bacterial protein and as such can be expected to produce an immune response (Rogers et al., 2005). Surprisingly, a single prior exposure of CocE did not elicit a significant antibody response and did not change CocE's effectiveness (Fig. 4). Three prior CocE exposures once per week slightly increased the anti-CocE antibody titers, but CocE retained its ability to protect these mice from cocaine toxicity (Fig. 5). Immunization using CFA followed by IFA has been shown to enhance antibody responses (Alving et al., 1995; Koetzner et al., 2001; Shu et al., 2001). As a positive control group, mice immunized with Freund's adjuvant showed a large increase in antibody titers (i.e., 1000-fold), and CocE completely lost its ability to protect these immunized mice (i.e., 100% of mice died after cocaine administration). These findings may indicate that CocE is a weak antigen and can maintain its protective ability after multiple exposures.

However, four prior CocE exposures once per 2 weeks significantly increased the antibody titers and CocE partially lost its ability to protect mice from cocaine toxicity (i.e., 33–50% of mice exhibited convulsions and died) (Fig. 6). This regimen produced 100- to 1000-fold increases in the anti-CocE antibody titers, which were close to those observed in mice immunized with Freund's adjuvant. Interestingly, however, not every mouse expressing a 1000-fold higher titer exhibited reduced protective effects of CocE (Fig. 7). It is possible that CFA/IFA immunization promotes development of more efficient antibodies. Nevertheless, these experiments indicate that reduction of CocE's protective ability is correlated to the antibody titer elicited with multiple doses of CocE. Future studies using repeated administration of cocaine combined with postinjection of CocE can further address the question of whether other factors such as damage to the myocardium after each cocaine overdose exposure can affect the usefulness of repeated CocE in the treatment of cocaine toxicity.

In summary, this study demonstrates that CocE dose-dependently protects and reverses cocaine-induced convulsions and lethality in mice and provides in vivo evidence for the therapeutic potential of CocE in the treatment of acute cocaine toxicity. Nevertheless, repeated CocE exposures increased the risk of immunological effects and, in part, reduced CocE's protective ability. This functional study provides a pharmacological basis for future research and development of CocE mutants and/or pegylated CocE mutants that may have greatly improved thermostability and reduced immunogenicity (Harris and Chess, 2003). More important, the study provides the first evidence of using CocE as a treatment modality in acute cocaine toxicity after the induction of convulsions.

	Acknowledgements

 
We thank Dr. Gail Winger for assistance with the editing of manuscript and Justin Knorr and John Pascoe for excellent technical assistance.

	Footnotes

 
This study was supported by United States Public Health Service Grants DA-00254 and DA-021416.

Article, publication date, and citation information can be found at http://jpet.aspetjournals.org.

doi:10.1124/jpet.106.114223.

ABBREVIATIONS: BChE, butyrylcholinesterase; CocE, cocaine esterase; PBS, phosphate-buffered saline; IFA, incomplete Freund's adjuvant; CFA, complete Freund's adjuvant.

Address correspondence to: Dr. M. C. Ko, Department of Pharmacology, University of Michigan, 1301 MSRB III, Ann Arbor, MI 48109-0632. E-mail: mko{at}umich.edu

	References

Top Abstract Materials and Methods Results Discussion References

 

Alving CR, Koulchin V, Glenn GM, and Rao M (1995) Liposomes as carriers of peptide antigens: induction of antibodies and cytotoxic T lymphocytes to conjugated and unconjugated peptides. Immunol Rev 145: 5–31.[CrossRef][Medline]

Bauman JL and DiDomenico RJ (2002) Cocaine-induced channelopathies: emerging evidence on the multiple mechanisms of sudden death. J Cardiovasc Pharmacol Ther 7: 195–202.[Abstract/Free Full Text]

Benowitz NL (1993) Clinical pharmacology and toxicology of cocaine. Pharmacol Toxicol 72: 3–12.[Medline]

Bresler MM, Rosser SJ, Basran A, and Bruce NC (2000) Gene cloning and nucleotide sequencing and properties of a cocaine esterase from Rhodococcus sp. strain MB1. Appl Environ Microbiol 66: 904–908.[Abstract/Free Full Text]

Carrera MRA, Trigo JM, Wirsching P, Roberts AJ, and Janda KD (2005) Evaluation of the anticocaine monoclonal antibody GNC92H2 as an immunotherapy for cocaine overdose. Pharmacol Biochem Behav 81: 709–714.[CrossRef][Medline]

Cooper ZD, Narasimhan D, Sunahara RK, Mierzejewski P, Jutkiewicz EM, Larsen NA, Wilson IA, Landry DW, and Woods JH (2006) Rapid and robust protection against cocaine-induced lethality in rats by the bacterial cocaine esterase. Mol Pharmacol 70: 1885–1891.[Abstract/Free Full Text]

Crumb WJ Jr and Clarkson CW (1990) Characterization of cocaine-induced block of cardiac sodium channels. Biophys J 57: 589–599.

Daniels A, Ayala E, Chen W, Coop A, and Matsumoto RR (2006) N-[2-(m-methoxyphenyl)ethyl]-N-ethyl-2-(1-pyrrolidinyl)ethylamine (UMB 116) is a novel antagonist for cocaine-induced effects. Eur J Pharmacol 542: 61–68.[CrossRef][Medline]

Deng SA, de Prada P, and Landry DW (2002) Anticocaine catalytic antibodies. J Immunol Methods 269: 299–310.[CrossRef][Medline]

Dickerson TJ and Janda KD (2005) Recent advances for the treatment of cocaine abuse: central nervous system immunopharmacotherapy. AAPS Journal 7: E579–586.

Dhuna A, Pascual-Leone A, Langendorf F, and Anderson D (1991) Epileptogenic properties of cocaine in humans. Neurotoxicology 12: 621–626.[Medline]

Gasior M, Ungard JT, and Witkin JM (2000) Chlormethiazole: effectiveness against toxic effects of cocaine in mice. J Pharmacol Exp Ther 295: 153–161.[Abstract/Free Full Text]

Harris JM and Chess RB (2003) Effect of pegylation on pharmaceuticals. Natl Rev Drug Discov 2: 214–221.

Hoffman BJ, Mezey E, and Brownstein MJ (1991) Cloning of a serotonin transporter affected by antidepressants. Science (Wash DC) 254: 579–580.[Abstract/Free Full Text]

Kilty JE, Lorang D, and Amara SG (1991) Cloning and expression of a cocaine-sensitive rat dopamine transporter. Science (Wash DC) 254: 578–579.[Abstract/Free Full Text]

Koetzner L, Deng S, Sumpter TL, Weisslitz M, Abner RT, Landry DW, and Woods JH (2001) Titer-dependent antagonism of cocaine following active immunization in rhesus monkeys. J Pharmacol Exp Ther 296: 789–796.[Abstract/Free Full Text]

Kramer LD, Locke GE, Ogunyemi A, and Nelson L (1990) Cocaine-related seizures in adults. Am J Drug Alcohol Abuse 16: 307–317.[Medline]

Larsen NA, Turner JM, Stevens J, Rosser SJ, Basran A, Lerner RA, Bruce NC, and Wilson IA (2002) Crystal structure of a bacterial cocaine esterase. Nat Struct Biol 9: 17–21.[CrossRef][Medline]

Lynch TJ, Mattes CE, Singh A, Bradley RM, Brady RO, and Dretchen KL (1997) Cocaine detoxification by human plasma butyrylcholinesterase. Toxicol Appl Pharmacol 145: 363–371.[CrossRef][Medline]

Mattes CE, Lynch TJ, Singh A, Bradley RM, Kellaris PA, Brady RO, and Dretchen KL (1997) Therapeutic use of butyrylcholinesterase for cocaine intoxication. Toxicol Appl Pharmacol 145: 372–380.[CrossRef][Medline]

Nettleton J and Wang GK (1990) pH-dependent binding of local anesthetics in single batrachotoxin-activated Na⁺ channels: cocaine vs. quaternary compounds. Biophys J 58: 95–106.

National Institute on Drug Abuse (2004) Cocaine Abuse and Addiction. NIDA Research Report Series. NIH Publication No. 99-4342 (Rev. Nov. 2004).

O'Leary ME and Chahine M (2002) Cocaine binds to a common site on open and inactivated human heart (Na(v)1.5) sodium channels. J Physiol (Lond) 541: 701–716.[Abstract/Free Full Text]

Pacholczyk T, Blakely RD, and Amara SG (1991) Expression cloning of a cocaine-and antidepressant-sensitive human noradrenaline transporter. Nature (Lond) 350: 350–354.[CrossRef][Medline]

Pan Y, Gao D, Yang W, Cho H, Yang G, Tai HH, and Zhan CG (2005) Computational redesign of human butyrylcholinesterase for anticocaine medication. Proc Natl Acad Sci USA 102: 16656–16661.[Abstract/Free Full Text]

Ramamoorthy S and Blakely RD (1999) Phosphorylation and sequestration of serotonin transporters differentially modulated by psychostimulants. Science (Wash DC) 285: 763–766.[Abstract/Free Full Text]

Rogers CJ, Mee JM, Kaufmann GF, Dickerson TJ, and Janda KD (2005) Toward cocaine esterase therapeutics. J Am Chem Soc 127: 10016–10017.[CrossRef][Medline]

Shu Q, Bir SH, Gill HS, Duan E, Xu Y, Hillard MA, and Rowe JB (2001) Antibody response in sheep following immunization with Streptococcus bovis in different adjuvants. Vet Res Commun 25: 43–54.[CrossRef][Medline]

Sofuoglu M and Kosten TR (2005) Novel approaches to the treatment of cocaine addiction. CNS Drugs 19: 13–25.[CrossRef][Medline]

Substance Abuse and Mental Health Services Administration (2005) Overview of Findings from the 2004 National Survey on Drug Use and Health. Office of Applied Studies, NSDUH Series H-27, DHHS Publication No. SMA 05-4061, Rockville, MD.

Substance Abuse and Mental Health Services Administration (2006) Drug Abuse Warning Network, 2004: National Estimates of Drug-Related Emergency Department Visits. Office of Applied Studies, DAWN Series D-28, DHHS Publication No. SMA 06-4143, Rockville, MD.

Turner JM, Larsen NA, Basran A, Barbas CF III, Bruce NC, Wilson IA, and Lerner RA (2002) Biochemical characterization and structural analysis of a highly proficient cocaine esterase. Biochemistry 41: 12297–12307.[CrossRef][Medline]

Vocci FJ, Acri J, and Elkashef A (2005) Medication development for addictive disorders: the state of the science. Am J Psychiatry 162: 1432–1440.[Abstract/Free Full Text]

Wilson LD and Shelat C (2003) Electrophysiologic and hemodynamic effects of sodium bicarbonate in a canine model of severe cocaine intoxication. J Toxicol Clin Toxicol 41: 777–788.[CrossRef][Medline]

Wright SN, Wang SY, Kallen RG, and Wang GK (1997) Differences in steady-state inactivation between Na channel isoforms affect local anesthetic binding affinity. Biophys J 73: 779–788.

Zhang S, Rajamani S, Chen Y, Gong Q, Rong Y, Zhou Z, Ruoho A, and January CT (2001) Cocaine blocks HERG, but not KvLQT1+minK, potassium channels. Mol Pharmacol 59: 1069–1076.[Abstract/Free Full Text]

This article has been cited by other articles:

				D. Gao, D. L. Narasimhan, J. Macdonald, R. Brim, M.-C. Ko, D. W. Landry, J. H. Woods, R. K. Sunahara, and C.-G. Zhan Thermostable Variants of Cocaine Esterase for Long-Time Protection against Cocaine Toxicity Mol. Pharmacol., February 1, 2009; 75(2): 318 - 323. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) All Versions of this Article: jpet.106.114223v1 320/2/926    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ko, M.-C. Articles by Woods, J. H. Search for Related Content PubMed PubMed Citation Articles by Ko, M.-C. Articles by Woods, J. H.